DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Novartis
ViroMissile, Inc.
SAPU NANO (US) LLC
AccSalus Biosciences, Inc.
Chongqing Precision Biotech Co., Ltd
Novelty Nobility, Inc.
Mayo Clinic
Xencor, Inc.
Eli Lilly and Company
University of Southern California
Merck Sharp & Dohme LLC
Exelixis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
National Institutes of Health Clinical Center (CC)